• Earlier this week, Merck reported that the FDA approved KEYTRUDA and KEYTRUDA QLEX, each in combination with WELIREG, as adjuvant therapy for adults with clear cell renal cell carcinoma at intermediate-high or high risk of recurrence following surgery, based on disease‑free survival gains in the Phase 3 LITESPARK‑022 trial.
• This decision introduces the first approved pairing of a PD-1 inhibitor with a HIF-2α inhibitor and extends WELIREG into earlier-stage kidney cancer, broadening Merck’s oncology treatment footprint.
• We’ll now examine how this first-in-class PD-1 plus HIF-2α adjuvant approval may influence Merck’s existing investment narrative.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Merck Investment Narrative Recap

To own Merck, you have to believe its broad pipeline and business development can gradually reduce dependence on KEYTRUDA ahead of loss of exclusivity, while managing pricing and competitive pressures. The new KEYTRUDA plus WELIREG adjuvant approval in clear cell RCC supports that pipeline depth, but does not change the near term focus on how effectively Merck replaces future KEYTRUDA revenue and handles ongoing Gardasil softness and potential pricing or tariff headwinds.

Among recent announcements, the Phase 3 success of the once weekly islatravir and lenacapavir HIV regimen stands out alongside the RCC approval. Together, they underline why many investors see Merck’s late stage portfolio across oncology and infectious disease as the key catalyst, particularly as the company targets more than 20 new growth drivers to help bridge the eventual KEYTRUDA patent expiry.

Yet even with these wins, investors should still be aware of the risk that pricing pressure and future biosimilar competition could...

Merck's narrative projects $76.5 billion revenue and $23.7 billion earnings by 2029. This requires 5.1% yearly revenue growth and about a $14.8 billion earnings increase from $8.9 billion today.

Uncover how Merck's forecasts yield a $129.74 fair value, a 9% upside to its current price.

Exploring Other Perspectives

While the base case highlights KEYTRUDA plus WELIREG as a potential offset to future risks, the most cautious analysts were assuming only about US$71.3 billion in 2029 revenue and US$20.4 billion in earnings, reminding you that some see pricing and biosimilar pressure as a much bigger threat than consensus does.

Explore 9 other fair value estimates on Merck - why the stock might be worth as much as 92% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Merck research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Merck research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Merck's overall financial health at a glance.

Curious About Other Options?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.